Literature DB >> 19802736

miRNAs modulate the drug response of tumor cells.

XueMei Wu1, HuaSheng Xiao.   

Abstract

Chemotherapy is one of the major treatments of malignant carcinomas. However, its efficiency is affected by both intrinsic and acquired resistance to anticancer drugs. The cellular mechanisms of drug resistance include the overexpression of energy-dependent transporters that eject anticancer drugs from cells such as p-glycoprotein and multidrug resistance related protein (MRP), the mutation of drug targets, the activation of DNA repair pathways, the defects in cellular death pathways and so on. The genetic and epigenetic changes of these genes can lead to cancer drug resistance. Among these mechanisms, microRNAs (miRNAs) which are critical and essential for many important processes such as development, differentiation, and even carcinogenesis have been reported to regulate the chemo-sensitivity of tumor cells. In this paper we briefly review the relationship between miRNA and cancer drug resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802736     DOI: 10.1007/s11427-009-0114-4

Source DB:  PubMed          Journal:  Sci China C Life Sci        ISSN: 1006-9305


  16 in total

1.  MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.

Authors:  Ji-Qun Geng; Xiao-Chen Wang; Long-Fei Li; Jun Zhao; Song Wu; Gui-Ping Yu; Kou-Jun Zhu
Journal:  Tumour Biol       Date:  2015-09-10

Review 2.  Non-coding RNAs as theranostics in human cancers.

Authors:  Roxana S Redis; Ioana Berindan-Neagoe; Victor I Pop; George A Calin
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

3.  MicroRNA-130a reduces drug resistance in breast cancer.

Authors:  Jin Huang; Min Zhao; Hongguang Hu; Jin Wang; Lin Ang; Li Zheng
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

4.  Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing several pro-apoptotic proteins.

Authors:  Yateng Tie; Chong Chen; Yanli Yang; Zhen Qian; Hang Yuan; Huan Wang; Haili Tang; Yao Peng; Xilin Du; Bin Liu
Journal:  Oncol Lett       Date:  2018-04-02       Impact factor: 2.967

5.  Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells.

Authors:  Xue-mei Wu; Xiang-qiang Shao; Xian-xin Meng; Xiao-na Zhang; Li Zhu; Shi-xu Liu; Jian Lin; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

6.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31

7.  MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.

Authors:  Spencer I Kozinn; Niall J Harty; Jessica M Delong; Christina Deliyiannis; Tanya Logvinenko; Ian C Summerhayes; John A Libertino; Antonia H Holway; Kimberly M Rieger-Christ
Journal:  Genes Cancer       Date:  2013-01

8.  Role of microRNAs in Predicting the Prognosis of Cervical Cancer Cases: A Systematic Review and Meta-Analysis.

Authors:  Sasidharanpillai Sabeena; Nagaraja Ravishankar
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

Review 9.  microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review).

Authors:  Yan-Wen Jiang; Liang-An Chen
Journal:  Mol Med Rep       Date:  2012-02-03       Impact factor: 2.952

10.  miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.

Authors:  Y Shen; P Wang; Y Li; F Ye; F Wang; X Wan; X Cheng; W Lu; X Xie
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.